Epstein-Barr Virus Infections Clinical Trial
Official title:
Autologous EBV Specific CTLs for Therapy of Severe Chronic EBV Infection
Severe chronic active Epstein-Barr virus (SCAEBV) is a rare Epstein-Barr virus (EBV or
commonly known as mono or the kissing disease) associated disorder. This disorder may cause
chronic tiredness and fevers and sometimes be complicated by life threatening problems such
as multi-organ failure, chronic (ongoing) pneumonia, and lymphoproliferative diseases
(diseases involving the lymph nodes which could eventually show up as leukemia or a tumor).
The reasons for the body's inability to control the EBV infection are still unknown and no
effective treatment is currently available.
This research study uses Epstein-Barr virus (EBV) specific cytotoxic T lymphocytes (CTLs). We
want to see if we can grow special white blood cells, called T cells, that have been trained
to kill EBV infected cells in the laboratory and see if these cells may help control the EBV
infection when given back to the patient.
The purpose of this study is to find the largest safe dose of EBV specific CTLs, to learn
what the side effects are, and to see whether this therapy might help the body fight off the
SCAEBV infection.
Ten to sixty ml (2-12 teaspoons) of blood will be collected from the patient which we use to
grow the T cells. These T cells are then stimulated with EBV infected cells (which have been
treated with radiation so that they cannot grow). This stimulation trains the T cells to kill
EBV infected cells. We then test the T cells to make sure that they kill the EBV infected
cells.
Therapy can take place in one of the specifically designated outpatient clinics so hospital
admission is not required. First, patients will be given doses of Tylenol (for any
aches/pains) and Benadryl (for any minor allergic reactions such as itching/rash). Next, the
T cells will be injected into a vein over a 10 minute period. Patients will be closely
watched for any side effects.
If a patient shows some response to the treatment they may receive up to three additional T
cell injections at three month intervals. Patients will need to be seen every other week in
the clinic for six weeks after the injection. Following that, patients will either be seen in
the clinic or contacted by one of the research staff working on this study, once a month for
one year.
To learn more about the way the T cells are working and how long they last in the body, an
extra 40 mls(8 teaspoonfuls) of blood will be taken at these visits. Additionally, 3 mls (1/2
teaspoonful) of blood will be taken prior to the infusion and monthly thereafter to conduct a
CBC (a test to look at the components of the blood).
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01256853 -
Modified Vaccinia Ankara (MVA) Vaccine Study
|
Phase 1 | |
Completed |
NCT00070785 -
Protein Studies of the Epstein-Barr Virus in Ethnically Diverse Populations
|
N/A | |
Recruiting |
NCT01248598 -
The Prevelance Rate of Human Cytomegalovirus (HCMV), Epstein-Barr Virus (EBV) and Human Herpes Virus (HHV-6) in a Saliva of the Patient With Periodantitis
|
N/A | |
Completed |
NCT00701922 -
Surveillance Study of Viral Infections Following Lung Transplantation
|
N/A | |
Recruiting |
NCT02580539 -
A Study of the Safety and Efficacy of EBV Specific T-cell Lines
|
Phase 1/Phase 2 | |
Completed |
NCT03546101 -
Early Detection of Epstein-Barr Virus Related Disease.
|
||
Recruiting |
NCT05183490 -
R-MVST Cells for Treatment of Viral Infections
|
Phase 1 | |
Completed |
NCT00058812 -
Giving Epstein-Barr Virus (EBV) Specific Killer T Lymphocytes to Patients Who Have Had Donor Marrow Grafts
|
Phase 1 | |
Completed |
NCT01094405 -
Efficacy of Recombinant Epstein-Barr Virus (EBV) Vaccine in Patients With Nasopharyngeal Cancer Who Had Residual EBV DNA Load After Conventional Therapy
|
Phase 2 | |
Terminated |
NCT05305040 -
Study of Posoleucel (ALVR105,Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant
|
Phase 2/Phase 3 | |
Completed |
NCT02335437 -
Chronic Fatigue Following Acute Epstein-Barr Virus Infection in Adolescents
|
N/A | |
Completed |
NCT06002802 -
Study on Infectious Mononucleosis in Munich
|
||
Recruiting |
NCT04507477 -
Ex-vivo Delivery of Rituximab to Prevent PTLD in EBV Mismatch Lung Transplant Recipients: A Pilot Trial
|
Phase 1/Phase 2 | |
Recruiting |
NCT03266653 -
EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection
|
Phase 2 | |
Completed |
NCT00963248 -
EBV Infection as a Risk Factor for PTLD in Pediatric and Adult Renal Transplant Recipients
|
N/A | |
Enrolling by invitation |
NCT06027879 -
Anti-viral T-cell Therapy by Gamma Capture
|
Phase 1/Phase 2 | |
Recruiting |
NCT05592626 -
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT02715752 -
A Retrospective Chart Review Study of Gene-Eden-VIR/Novirin
|
N/A | |
Completed |
NCT01070797 -
Administration of Rapidly Generated Multivirus-specific Cytotoxic T-Lymphocytes (VIRAGE)
|
Phase 1 | |
Completed |
NCT00058604 -
Prevention and Treatment of Epstein-Barr Virus (EBV) Lymphoma Following a Solid Organ Transplant Using EBV Specific Cytotoxic T Lymphocytes (CTLs).
|
Phase 1 |